Xenon Pharmaceuticals Inc.
SEC CIK 1582313 · XENE · last insider filing 2026-06-08
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Patou Gary | Director | filed 2014 - 2026 |
| Cannon Gillian | Director | filed 2023 - 2026 |
| Machado Patrick | Director | filed 2020 - 2026 |
| Svoronos Dawn | Director | filed 2016 - 2026 |
| Gannon Steven | Director | filed 2015 - 2026 |
| Gover Justin D. | Director | filed 2023 - 2026 |
| Garofalo Elizabeth A. | Director | filed 2021 - 2026 |
| Mortimer IAN | Director · PRESIDENT, CEO & INTERIM CFO | filed 2014 - 2026 |
| Azab Mohammad | Director | filed 2014 - 2023 |
| Pimstone Simon N. | Director · President, CEO and Director | filed 2014 - 2023 |
| Hayden Michael R | Director | filed 2014 - 2021 |
| Holler Frank A | Director | filed 2014 - 2021 |
| Tarnow Michael M | Director | filed 2014 - 2021 |
| Desjardins Clarissa | Director | filed 2020 - 2020 |
| Scheller Richard H | Director | filed 2015 - 2019 |
| Evans Johnston L | Director | filed 2014 - 2015 |
| Stein Evan A. | Director | filed 2014 - 2015 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Difabio Andrea | Chief Legal Officer | filed 2022 - 2026 |
| Kenney Christopher John | Chief Medical Officer | filed 2021 - 2026 |
| Cline Darren S | Chief Commercial Officer | filed 2025 - 2026 |
| Kelly Thomas Patrick | Chief Financial Officer | filed 2025 - 2025 |
| Aulin Sherry | Chief Financial Officer | filed 2021 - 2024 |
| Robin Sherrington | See Remarks | filed 2014 - 2024 |
| Empfield James R. | SVP, Drug Discovery | filed 2016 - 2024 |
| Von Seggern Christopher | Chief Commercial Officer | filed 2020 - 2024 |
| Aycardi-Fonseca Ernesto | Chief Medical Officer | filed 2018 - 2020 |
| Cohen Charles J. | VP, Biology | filed 2014 - 2018 |
| Goldberg Y. Paul | VP, Clinical Development | filed 2014 - 2017 |
| Winquist Raymond | Head, Translational Research | filed 2016 - 2017 |
| Corraini Karen G. | See Remarks | filed 2014 - 2015 |
| Bridger Gary | EVP, Research & Development | filed 2014 - 2014 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.